|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2003-7-21
|
|
pubmed:abstractText |
131I-Metaiodobenzylguanidine (131I-MIBG) can be used systemically to treat malignant pheochromocytoma. To improve outcome, the authors used higher levels of activity of 131I-MIBG than previously reported. The authors reported the response rates and toxicity levels in patients with malignant pheochromocytoma or paraganglioma who were treated with high-dose 131I-MIBG.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2003 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
98
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
239-48
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:12872341-3-Iodobenzylguanidine,
pubmed-meshheading:12872341-Adolescent,
pubmed-meshheading:12872341-Adrenal Gland Neoplasms,
pubmed-meshheading:12872341-Adult,
pubmed-meshheading:12872341-Antineoplastic Agents,
pubmed-meshheading:12872341-Child,
pubmed-meshheading:12872341-Dose-Response Relationship, Radiation,
pubmed-meshheading:12872341-Female,
pubmed-meshheading:12872341-Humans,
pubmed-meshheading:12872341-Male,
pubmed-meshheading:12872341-Middle Aged,
pubmed-meshheading:12872341-Paraganglioma,
pubmed-meshheading:12872341-Pheochromocytoma,
pubmed-meshheading:12872341-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma.
|
|
pubmed:affiliation |
Department of Medicine, University of California-San Francisco, San Francisco, California, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Evaluation Studies
|
